Cosmo has a deep and broad expertise in the development of gastro-intestinal (GI) pharmaceutical products with a specific focus on Inflammatory Bowel Disease, based on the company’s innovative and proprietary MMX® technology. Most recently the Company has extended its expertise to other colon applications, with a special focus on endoscopy support targeted at making endoscopies easier, faster, safer and more effective.

The Company has built a successful and profitable pharmaceutical manufacturing business manufacturing products for international companies and in 2006 trebled its manufacturing capacity by adding a state-of-the-art, FDA-approved plant (for the production of Lialda®/Mezavant® and Uceris/Cortiment®), intended for the manufacturing of its own products.

The company’s proprietary MMX® technology is at the core of the product pipeline and was developed from its expertise in formulating and manufacturing GI pharmaceutical products for international clients. The research led to new patents that increased the efficacy of existing pharmaceutical products by modifying their formulations and tailoring their optimized delivery systems.

The company is engaged in the following activities:

Product Pipeline

Development, licensing and commercialization of proprietary pharmaceutical products, primarily focused on the treatment of Inflammatory Bowel Diseases, colon infections, other colon diseases and endoscopy support. Click here to read more.


Manufacturing of pharmaceutical products for third parties and the provision of related services. Click here to read more.


MMX® Multi Matrix Technology. Click here to read more.

Delivered by Investis – link to website (opens in a new window)